Results 311 to 320 of about 12,986,553 (373)

Incidence and Predictors of Clinical Outcomes in Real-Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow-Up Results of the ANATOLIA-AF Study. [PDF]

Clin Cardiol
Kocabaş U, Ergin I, Sönmez SC, Yavuz V, Murat S, Özdemir IH, Genç Ö, Tüner H, Meriç BK, Aslan O, Dal A, Taşkın U, Şen T, İbişoğlu E, Erdoğan A, Özgeyik M, Demir M, Urgun ÖD, Doğduş M, Çakal S, Çayırlı S, Güler A, Karabulut D, Dalgıç O, Murat B, Karabulut U, Öztekin GMY, Biter Hİ, Sinan ÜY, Barış VÖ, Kaplan M, Altın C, Kıvrak T.   +32 more
europepmc   +1 more source

Isoquercetin and Zafirlukast Cooperatively Suppress Tumor Growth and Thromboinflammatory Signaling in a Xenograft Model of Ovarian Cancer

The FASEB Journal, Volume 40, Issue 1, 15 January 2026.
Treatment using either the thiol isomerase inhibitor isoquercetin or zafirlukast lowers tissue factor levels, decreases VEGF, inhibits PD‐L1, and TMEM176B in a xenograft model of ovarian cancer. A combination of the two agents, at threefold lower concentrations than either drug, significantly enhanced the inhibition further, suggesting a dual action of
Justine A. Keovilay, Jason W. Hoskins, Jean‐Pierre Kinet, Thomas C. Lines, Daniel R. Kennedy   +4 more
wiley   +1 more source

Venous thromboembolism treatment failure during use of factor Xa inhibitors-association with thoracic outlet syndrome and development of chronic thromboembolic pulmonary hypertension. [PDF]

Ann Med
Kaksonen M, Simonen P, Lassila R, Pentikäinen M.   +3 more
europepmc   +1 more source

Perioperative Factor Xa Inhibitor Discontinuation for Patients Undergoing Procedures With Minimal or Low Bleeding Risk.

JAMA Netw Open
Lee SR, Lee KY, Park JS, Lee YS, Oh YS, Han SJ, Namgung J, Lee JH, Lim WH, Ahn MS, Kwon S, Ahn HJ, Oh S, Lip GYH, Choi EK, PERIXa Investigators.   +15 more
europepmc   +1 more source

Development of a Medication-Use Evaluation Template for Andexanet Alfa in the Reversal of Anticoagulation With Factor Xa Inhibitors. [PDF]

J Pharm Pract
Fera T, Burnett A, Grandoni J, Moore MR, Nussbaum BB, Pollack CV, Rose AE, Spinler SA, Streiff MB, Turck CJ, Fanikos J.   +10 more
europepmc   +1 more source

Direct Optical Detection of Factor Xa Activity in Minimally Processed Whole Blood

Cartwright AP, Wollant BC, York ES, Zheng L, Yee S, Chau HC, Batsuli G, Soh HT.   +7 more
europepmc   +1 more source

Design, Synthesis, and In Vitro and In Silico Study of New Hybrid 1-(2-(4-Arylthiazol-2-yl)hydrazineylidene)-5,6-dihydro-4<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-2-ones as Factor Xa and Factor XIa Inhibitors. [PDF]

Molecules
Skoptsova AA, Geronikaki A, Petrou A, Novichikhina NP, Podoplelova NA, Bykov GA, Anis'kov AA, Soloveva SA, Shikhaliev KS.   +8 more
europepmc   +1 more source

3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors. [PDF]

J Thromb Thrombolysis
Hays WB, Billups K, Nicholson J, Bailey AM, Gregory H, Weeda ER, Weant KA.   +6 more
europepmc   +1 more source

The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases. [PDF]

Sci Rep
Hamada S, Muramoto K, Akaike K, Okabayashi H, Masunaga A, Tomita Y, Ichiyasu H, Sakagami T.   +7 more
europepmc   +1 more source

Heavy menstrual bleeding on direct factor Xa inhibitors: the MEDEA randomized clinical trial. [PDF]

Res Pract Thromb Haemost
Hamulyák EN, Wiegers HMG, Hutten BA, de Lange ME, Timmermans A, Westerweel PE, Nijziel MR, Klok FA, Hovens MM, Kamphuisen PW, Büller HR, Middeldorp S, Scheres LJJ.   +12 more
europepmc   +1 more source